Ring Therapeutics Raises $117 Million in Series B Funding to Expand Novel Vector Platform
Ring's novel vector Anellogy™ platform harnesses unique properties of anelloviruses to create a pipeline of redosable vectors compatible with the human immune system to target specific tissues Ring's platform is the first disruptive advance in gene therapy in more than 50 years, since the discovery of AAV Ring has built the world's first and only vertically integrated anellovirus database with thousands of newly discovered vector candidates to produce programmable medicines C